BRISTOL-MYERS SQUIBB COMPANY Deferred Federal Income Tax Expense (Benefit)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Deferred Federal Income Tax Expense (Benefit) of -$1.11 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY deferred federal income tax expense (benefit) for fiscal 2025 was -$1.11B.
- BRISTOL-MYERS SQUIBB COMPANY deferred federal income tax expense (benefit) for fiscal 2024 was -$2.19B.
- BRISTOL-MYERS SQUIBB COMPANY deferred federal income tax expense (benefit) for fiscal 2023 was -$2.34B.
- BRISTOL-MYERS SQUIBB COMPANY deferred federal income tax expense (benefit) for fiscal 2022 was -$2.89B.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$1.11B 10-K · filed 2026-02-11 | |
| 2024-12-31 | -$2.19B 10-K · filed 2026-02-11 | |
| 2023-12-31 | -$2.34B 10-K · filed 2026-02-11 | |
| 2022-12-31 | -$2.89B 10-K · filed 2025-02-12 | |
| 2021-12-31 | -$1.25B 10-K · filed 2024-02-13 | |
| 2020-12-31 | $229.00M 10-K · filed 2023-02-14 | |
| 2019-12-31 | -$113.00M 10-K · filed 2022-02-09 | |
| 2018-12-31 | -$51.00M 10-K · filed 2021-02-10 | $29.00M 10-K · filed 2019-02-25 |
| 2017-12-31 | $541.00M 10-K · filed 2020-02-24 | $1.06B 10-K · filed 2018-02-13 |
| 2016-12-31 | -$101.00M 10-K · filed 2019-02-25 | |
| 2015-12-31 | -$394.00M 10-K · filed 2018-02-13 | |
| 2014-12-31 | -$403.00M 10-K · filed 2017-02-21 | |
| 2013-12-31 | -$390.00M 10-K · filed 2016-02-12 | |
| 2012-12-31 | -$1.16B 10-K · filed 2015-02-13 | |
| 2011-12-31 | $406.00M 10-K · filed 2014-02-14 | |
| 2010-12-31 | $438.00M 10-K · filed 2013-02-15 | |
| 2009-12-31 | $222.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |